GleamWall
中文EN

NRXP NRX Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1719406 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2,076.5%
TTM net income YoY48.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin40.5%
Operating margin-551.7%
Net margin-454.1%
FCF margin—
EBITDA margin-546.4%

Returns

ROE—
ROA-92.3%
ROIC (approx.)—
Asset turnover0.20x

Leverage & solvency

Liabilities / assets107.1%
Debt / equity—
Current ratio0.76x
Interest coverage-17.37x

Cash quality & payout

Operating cash flow / net income1.19x
Accruals ratio17.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312024Q32025-09-302024Q22025-06-302024Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.16M$1.10M$1.07M$1.02M$200,000$0$0$0
Cost of revenue$874,000$675,000$631,000$408,000$97,000$0$0$0
Gross profit$285,000$426,000$437,000$617,000$103,000$0$0$0
R&D expense$1.81M$2.12M$1.31M$558,000$1.43M$987,000$804,000$1.04M
SG&A expense$6.56M$4.75M$3.81M$4.57M$2.81M$2.74M$2.94M$2.60M
Operating income-$8.14M-$6.50M-$4.74M-$4.62M-$4.02M-$3.73M-$3.85M-$2.43M
Interest expense$239,000$240,000$233,000$671,000$0$0$0$0
Income tax$0$0$0$0$0$0$0$0
Net income-$2.17M-$16.52M-$1.43M$360,000-$5.89M-$17.58M-$5.51M-$9.08M
EBITDA-$8.08M-$6.44M-$4.68M-$4.58M-$4.00M-$3.73M-$3.85M-$2.43M
EPS (basic)-0.05-0.44-0.04—-0.27-0.98-0.34—
EPS (diluted)————————
Balance sheet
Cash & equivalents$19.82M$26.69M$6.71M$7.80M$7.18M$2.91M$5.55M$1.44M
Receivables$218,000$206,000$181,000$161,000$239,000——$0
Current assets$22.21M$29.16M$7.36M$8.89M$11.95M$4.59M$7.26M$3.30M
PP&E, net$901,000$919,000$259,000$63,000$69,000——$10,000
Goodwill$2.35M$1.79M$1.79M$1.79M$610,000——$0
Intangibles$787,000$832,000$879,000$925,000$1.78M——$0
Total assets$27.82M$34.16M$11.90M$12.96M$15.00M$4.84M$7.59M$3.65M
Current liabilities$29.25M$33.87M$25.18M$28.58M$40.59M$40.45M$32.75M$21.86M
Total liabilities$29.80M$34.33M$25.72M$28.89M$40.75M$40.45M$32.75M$26.87M
Shareholders' equity-$1.99M-$170,000-$13.82M-$15.94M-$25.75M-$35.62M-$25.16M-$23.22M
Shares outstanding43.21M43.16M33.47M31.73M27.68M19.47M17.12M14.59M
Cash flow statement
Operating cash flow-$6.71M-$8.88M-$4.29M-$3.71M-$2.89M-$4.03M-$3.48M-$2.10M
Capital expenditure-$1,000———$0$0$0$0
Free cash flow-$6.71M———-$2.89M-$4.03M-$3.48M-$2.10M
Investing cash flow$1,000-$684,000-$213,000-$249,000-$2.56M$0$0$0
Financing cash flow-$152,000$29.53M$3.42M$4.58M$9.73M$1.39M$7.58M$1.90M
Depreciation & amortization$62,000$66,000$63,000$42,000$26,000$0$1,000$1,000
Stock-based compensation$188,000$139,000$151,000$81,000$68,000$67,000$12,000$43,000

Free plan shows the latest 8 periods; Pro shows all 36 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.